BioSpace News Archive

BioSpyder Technologies, Inc. has been awarded the contract to perform High Throughput Compatible Gene Expression Profiling for Species of Ecotoxicological Relevance by the United States Environmental Protection Agency (EPA) Center for Computational Toxicology and Exposure (CCTE).

Greenwich LifeSciences, Inc. today provides an update on the upcoming Phase III clinical trial FLAMINGO-01.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights

Edgewise Therapeutics Reports Third Quarter 2021 Financial Results

Aphios Corporation today announced that it has been granted Chinese Patent No. 201811111996.8 by China National Intellectual Property Administration on October 26, 2021.

Medexus Pharmaceuticals Inc. announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President & Chief Executive Officer will present at the H.C. Wainwright 7th Annual Israel Virtual Conference.

Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the pricing of an underwritten registered public offering of 1,204,375 shares of its common stock at a price to the public of $8.00 per share.